Physician profile
Paul M Carter
NPI 1881691988
$1,398.70
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $118 · 2021: $33.17 · 2022: $101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $976.79 | 2019 | |
| Smith+Nephew, INC. | $115.31 | 2019-2022 | |
| Kci USA, INC. | $62.31 | 2020-2022 | |
| Convatec INC. | $42.92 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $40.02 | 2019 | |
| Aroa Biosurgery Incorporated | $39.18 | 2019 | |
| Organogenesis INC. | $36.93 | 2022 | |
| Ovik Health, LLC | $29.00 | 2019-2020 | |
| Philips North America LLC | $20.83 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $19.41 | 2019 | |
| Teleflex LLC | $16.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.